Antigen presentation was carried out mainly by migratory and dLN-resident conventional type 2 DCs (cDC2s) and significantly more potent antitumor responses were triggered in both prophylactic and therapeutic tumor models in a CD4<sup>+</sup> and CD8<sup>+</sup> T cell-dependent fashion. The gene discussed is CD8A; the disease is neoplasm.